CRISPR Archives

Biotech By Matthew Herper and Megan Molteni

Return of the mammoth? George Church-backed company launches with $15 million for elephant-sized quest

In the Lab By Megan Molteni

A new technology, based on a quirk of evolutionary biology, may be the next big thing for CRISPR

STAT Summit By Megan Molteni

Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

The Readout LOUD By Meg Tirrell, Adam Feuerstein and Damian Garde

Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails

Biotech By Adam Feuerstein

CRISPR Therapeutics, Nkarta to jointly develop engineered natural killer cells as cancer treatments

Biotech By Megan Molteni

Beam Therapeutics unveils new CRISPR base editing tool to target the sickle cell mutation

First Opinion By Patrick Skerrett

Q&A with ‘Code Breaker’ author Walter Isaacson on CRISPR, patents, and more

First Opinion Podcast By Patrick Skerrett

Listen: Walter Isaacson on CRISPR rivals and a Covid truce

The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein

Listen: J&J’s imminent vaccine data, CRISPR’s confusing boom, and navigating scientific misinformation

First Opinion By Chris Bakerlee

Mother Nature is not ‘the ultimate bioterrorist’

Biotech By Adam Feuerstein

Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible

Biotech By Adam Feuerstein

CRISPR Therapeutics’ CAR-T treatment shows encouraging results, but one death is tied to therapy

First Opinion By Patrick Skerrett

The CRISPR Nobel was about more than two women scientists. It was about all of them

In the Lab By Andrew Joseph

The CRISPR story: How a basic research discovery changed science and led to a Nobel

In the Lab By Elizabeth Cooney

‘A terrific choice’: George Church salutes fellow CRISPR pioneers’ historic Nobel win

Health By Matthew Herper

Jennifer Doudna, now a Nobel winner, on CRISPR and its role in medical research

Jennifer A. Doudna und Emmanuelle Charpentier

In the Lab By Sharon Begley and Elizabeth Cooney

Two female CRISPR scientists make history, winning Nobel Prize in chemistry for genome-editing discovery

In the Lab By Sharon Begley

Dust off the crystal ball: It’s time for STAT’s 2020 Nobel Prize predictions

Genetic engineering and gene manipulation concept.

Biotech By Andrew Joseph

Patent board delivers blow to University of California over its CRISPR invention claims

First Opinion By Josephine Johnston

The U.S. must do some heavy lifting to prepare for heritable genome editing

Health By Andrew Joseph

Expert panel lays out guidelines for germline editing, while warning against pursuit of ‘CRISPR babies’

In the Lab By Gideon Gil

Virtual Event: CRISPR’s forward march

In the Lab By Sharon Begley

Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases

In the Lab By Sharon Begley

In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys

Biotech By Jonathan Saltzman — Boston Globe

Most Read

Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021

In a first for genome editing, Intellia Therapeutics reports positive early data on in vivo CRISPR therapy

CRISPR rivals put patents aside to help in fight against Covid-19

Lab tests show risks of using CRISPR gene editing on embryos

DNA sleuths read the coronavirus genome, tracing its origins and looking for dangerous mutations

CRISPR babies scientist He Jiankui should not be villainized — or headed to prison

You had questions for David Liu about CRISPR, prime editing, and advice to young scientists. He has answers

Vaccines don’t work against some viruses. CRISPR might one day fix that

All Coverage

Return of the mammoth? George Church-backed company launches with $15 million for elephant-sized quest

A new technology, based on a quirk of evolutionary biology, may be the next big thing for CRISPR

Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails

CRISPR Therapeutics, Nkarta to jointly develop engineered natural killer cells as cancer treatments

Beam Therapeutics unveils new CRISPR base editing tool to target the sickle cell mutation

Q&A with ‘Code Breaker’ author Walter Isaacson on CRISPR, patents, and more

Listen: Walter Isaacson on CRISPR rivals and a Covid truce

Listen: J&J’s imminent vaccine data, CRISPR’s confusing boom, and navigating scientific misinformation

Mother Nature is not ‘the ultimate bioterrorist’

Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible

CRISPR Therapeutics’ CAR-T treatment shows encouraging results, but one death is tied to therapy

The CRISPR Nobel was about more than two women scientists. It was about all of them

The CRISPR story: How a basic research discovery changed science and led to a Nobel

‘A terrific choice’: George Church salutes fellow CRISPR pioneers’ historic Nobel win

Jennifer Doudna, now a Nobel winner, on CRISPR and its role in medical research

Two female CRISPR scientists make history, winning Nobel Prize in chemistry for genome-editing discovery

Dust off the crystal ball: It’s time for STAT’s 2020 Nobel Prize predictions

Patent board delivers blow to University of California over its CRISPR invention claims

The U.S. must do some heavy lifting to prepare for heritable genome editing

Expert panel lays out guidelines for germline editing, while warning against pursuit of ‘CRISPR babies’

Virtual Event: CRISPR’s forward march

Gene-editing discovery could point the way toward a ‘holy grail’: cures for mitochondrial diseases

In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys

Verve, raising another $63 million, seeks to advance gene-editing treatment for heart disease